However, in one small study, addition of the pan-RAF inhibitor RAF265 or the selective BRAF inhibitor encorafenib to the MEK inhibitor binimetinib did not appear to influence the incidence of retinopathy [9]. This evidence concerns the gene BRAF and retinal disorder.